{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:32:15Z","timestamp":1790087535757,"version":"4.0.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["TDNCC18K0"],"award-info":[{"award-number":["TDNCC18K0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jcf.2026.02.005","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T20:28:02Z","timestamp":1771100882000},"page":"489-494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of elexacaftor\/tezacaftor\/ivacaftor on gastrointestinal outcomes, inflammation, exocrine pancreatic function and fat malabsorption: Report of PROMISE pediatric substudy"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0371-0986","authenticated-orcid":false,"given":"Nicole","family":"Green","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuong","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5077-7625","authenticated-orcid":false,"given":"Sarah Jane","family":"Schwarzenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7645-4685","authenticated-orcid":false,"given":"Michael","family":"Narkewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3789-1241","authenticated-orcid":false,"given":"Jessica","family":"Pittman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4057-6592","authenticated-orcid":false,"given":"Felix","family":"Ratjen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8105-614X","authenticated-orcid":false,"given":"Margaret","family":"Rosenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8864-6751","authenticated-orcid":false,"given":"Lucas","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya","family":"Heltshe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah S.","family":"Lusman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2026.02.005_bib0001","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1056\/NEJMra043184","article-title":"Cystic fibrosis","volume":"352","author":"Rowe","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2026.02.005_bib0002","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S2213-2600(12)70057-7","article-title":"A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect","volume":"1","author":"Boyle","year":"2013","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2026.02.005_bib0003","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cgh.2012.11.006","article-title":"Gastrointestinal complications of cystic fibrosis","volume":"11","author":"Gelfond","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jcf.2026.02.005_bib0004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174463","article-title":"Abdominal symptoms in cystic fibrosis and their relation to genotype, history, clinical and laboratory findings","volume":"12","author":"Tabori","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jcf.2026.02.005_bib0005","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/MPG.0000000000003904","article-title":"CFTR modulators for the gastroenterologist","volume":"77","author":"Sabharwal","year":"2023","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jcf.2026.02.005_bib0006","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jcf.2022.10.006","article-title":"Multicenter prospective study showing a high gastrointestinal symptom burden in cystic fibrosis","volume":"22","author":"Moshiree","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.02.005_bib0007","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1513\/AnnalsATS.201408-393OC","article-title":"A systematic review of factors associated with health-related quality of life in adolescents and adults with cystic fibrosis","volume":"12","author":"Habib","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2026.02.005_bib0008","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.jpeds.2012.08.040","article-title":"Better nutritional status in early childhood is associated with improved clinical outcomes and survival in patients with cystic fibrosis","volume":"162","author":"Yen","year":"2013","journal-title":"J Pediatr"},{"key":"10.1016\/j.jcf.2026.02.005_bib0009","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-Tezacaftor-Ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2026.02.005_bib0010","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jcf.2021.02.003","article-title":"PROMISE: working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy","volume":"20","author":"Nichols","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2026.02.005_bib0011","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jcf.2022.10.003","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: report of promise-GI","volume":"22","author":"Schwarzenberg","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.02.005_bib0012","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/MCP.0b013e3283659ef2","article-title":"Intestinal complications of cystic fibrosis","volume":"19","author":"Borowitz","year":"2013","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jcf.2026.02.005_bib0013","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/MPG.0000000000003173","article-title":"Gastrointestinal factors associated with hospitalization in infants with cystic fibrosis: results from the baby observational and nutrition study","volume":"73","author":"Sathe","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"10.1016\/j.jcf.2026.02.005_bib0014","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis: a Clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.jcf.2026.02.005_bib0015","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/j.1536-4801.1994.tb11298.x","article-title":"The acid steatocrit: a much improved method","volume":"19","author":"Tran","year":"1994","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jcf.2026.02.005_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2025.01.010","article-title":"Longer term follow-up of abdominal symptoms (CFAbd-Score) after initiation of Elexacaftor \/Tezacaftor \/ Ivacaftor in adults with cystic fibrosis","author":"Caley","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2026.02.005_bib0017","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jcf.2023.10.001","article-title":"Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged \u226512 years - the RECOVER study","volume":"23","author":"Mainz","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.02.005_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1167407","article-title":"Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor\/tezacaftor\/ivacaftor using the novel CFAbd-day2day questionnaire","volume":"14","author":"Mainz","year":"2023","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.jcf.2026.02.005_bib0019","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jcf.2024.07.013","article-title":"Estimating minimal clinically important difference (MCID) for gastrointestinal symptoms in cystic fibrosis","volume":"23","author":"Lee","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.02.005_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.877118","article-title":"Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-score","volume":"13","author":"Mainz","year":"2022","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.jcf.2026.02.005_bib0021","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jcf.2021.07.002","article-title":"Utilization of electronic patient-reported outcome measures in cystic fibrosis research: application to the GALAXY study","volume":"20","author":"Sathe","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2026.02.005_bib0022","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/MPG.0000000000000414","article-title":"PedsQL gastrointestinal symptoms module: feasibility, reliability, and validity","volume":"59","author":"Varni","year":"2014","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"10.1016\/j.jcf.2026.02.005_bib0023","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","article-title":"KIWI Study Group. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study","volume":"4","author":"Davies","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.jcf.2026.02.005_bib0024","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jcf.2019.03.009","article-title":"KLIMB study group. An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB)","volume":"18","author":"Rosenfeld","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2026.02.005_bib0025","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-2600(18)30202-9","article-title":"ARRIVAL study group. Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study","volume":"6","author":"Rosenfeld","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.jcf.2026.02.005_bib0026","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000530261","article-title":"Prenatal Cystic Fibrosis transmembrane conductance regulator modulator therapy: a promising way to change the impact of Cystic fibrosis","volume":"50","author":"G\u00f3mez-Montes","year":"2023","journal-title":"Fetal Diagn Ther"},{"issue":"4","key":"10.1016\/j.jcf.2026.02.005_bib0027","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jcf.2022.04.005","article-title":"A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.02.005_bib0028","doi-asserted-by":"crossref","DOI":"10.1513\/AnnalsATS.202501-103OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in 6 to 11-year-olds with cystic fibrosis","author":"Pittman","year":"2025","journal-title":"Ann Am Thorac Soc"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326000342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326000342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T15:46:41Z","timestamp":1781884001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326000342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1569199326000342"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.02.005","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of elexacaftor\/tezacaftor\/ivacaftor on gastrointestinal outcomes, inflammation, exocrine pancreatic function and fat malabsorption: Report of PROMISE pediatric substudy","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}